Liraglutide is the first once-daily long-acting analogue with 97% identity to the naturally occurring human GLP-1, containing a palmitoyl chain at Lys26 through a γ-glutamyl spacer along with a Lys to Arg substitution at position 34, and it has been constructed for the treatment of diabetes and obesity [19]. This evidence concerns the gene GLP1R and diabetes mellitus.